Anti-LKM (anti-liver-kidney-microsome) antibodies
Nature and antigenic targets
Anti-LKM antibodies recognize smooth endoplasmic reticulum enzymes in hepatocytes and renal tubular cells. Their designation reflects the fluorescence pattern observed in indirect immunofluorescence: a homogeneous staining of the hepatic cytoplasm and fluorescence of the renal proximal tubules, sparing the glomeruli. This distinctive anatomical distribution distinguishes them from other hepatic autoantibodies.
| Subtype | Antigenic target | Main association | Clinical relevance |
|---|---|---|---|
| Anti-LKM-1 | Cytochrome P450 2D6 (CYP2D6) | Autoimmune hepatitis type 2 (AIH-2) | Primary diagnostic marker; most frequent and clinically significant |
| Anti-LKM-2 | Cytochrome P450 2C9 (CYP2C9) | Drug-induced hepatitis (ticrynafen, tienilic acid) | Drug withdrawn from the market; very rare in current practice |
| Anti-LKM-3 | UDP-glucuronosyltransferases (UGTs) | Chronic Hepatitis Delta (HDV), Atypical HAI-2 | Rare; sometimes coexists with anti-LKM-1 |
Type 2 autoimmune hepatitis: clinical presentation
Autoimmune hepatitis type 2 is a chronic inflammatory liver disease mediated by cellular and humoral immunity. It differs from type 1 by several important clinical and biological characteristics that the clinician must be aware of to quickly guide the diagnostic workup.
| Features | Type 1 diabetes | Type 2 AI (anti-LKM-1) |
|---|---|---|
| Serological markers | ANA, ASMA (anti-actin) | Anti-LKM-1, anti-LC1 |
| Affected population | All ages; bimodal peak (young woman and adult aged 50-70) | Children and young adults; marked female predominance |
| Severity | Variable; often insidious | Often more acute and severe; faster progression to cirrhosis |
| Associated autoimmune diseases | Thyroiditis, vitiligo, type 1 diabetes | Type 1 diabetes, thyroiditis, autoimmune polyglandular syndrome |
| Response to corticosteroids | Good in most cases | Good, but more frequent relapses after stopping treatment. |
| Serum IgG | Elevated (activity marker) | Elevated; IgAs can also be increased |
Hepatic symptoms and presentation
The clinical presentation of HAI-2 is variable, ranging from an asymptomatic elevation of liver enzymes discovered incidentally to a picture of severe acute hepatitis. In advanced forms, signs of chronic liver failure may dominate the clinical picture.
- Persistent fatigue, asthenia, and general malaise, often the first symptoms
- Jaundice, dark urine, and pale stools in case of active disease
- Pain or discomfort in the upper right quadrant of the abdomen
- Nausea, anorexia, and moderate weight loss
- Joint pain and muscle pain, sometimes confused with connective tissue disease
- Rash, acne, or amenorrhea in young patients
- Hepatomegaly or splenomegaly on physical examination
- Signs of cirrhosis in advanced forms: ascites, palmar erythema, spider angiomas
Biological and serological evaluation
The diagnosis of AIH-2 relies on a combination of clinical, biological, serological, and histological criteria. No single marker is sufficient on its own. The International Autoimmune Hepatitis Group (revised IAIHG score) integrates all of these data to establish a probable or definitive diagnosis.
- Transaminases (ALT, AST): elevated, sometimes very highly in case of acute flare-up
- Total and conjugated bilirubin: elevated during active episodes
- Alkaline phosphatase (ALP) and GGT: moderately elevated; a predominant elevation suggests cholangitis
- Total serum IgG: elevated in more than 80% of cases of active HAI
- Anti-LKM-1 by indirect immunofluorescence (IIF): diagnostic reference method
- Anti-LC1 (anti-liver cytosol type 1 antibodies): often co-positive in AIH-2; useful if anti-LKM-1 is borderline
- CSF and ASMA: generally negative in pure HAI-2
- Viral serologies: HBV, HCV, HVD (to be excluded before confirming an autoimmune diagnosis)
- Ceruloplasmin and urinary copper: measure in children to rule out Wilson's disease
- Alpha-1-antitrypsin: to exclude in chronic liver disease of children
Anti-LKM-1 associated conditions
| Condition | Frequency of anti-LKM-1 | Remarks |
|---|---|---|
| Autoimmune hepatitis type 2 | 100 % (defining criterion) | Primary diagnostic marker; titer correlates with activity |
| Chronic hepatitis C | 5 to 10 % | Possible false positives; important distinction before interferon treatment |
| Hepatitis delta (HDV) | Rare (anti-LKM-3 plus characteristics) | HBV/HDV co-infection context; anti-LKM-3 associated |
| Autoimmune polyendocrine syndrome type 1 (APS-1) | Variable | AIRE mutations; HAI-2 frequent in this pediatric context |
| Drug-induced hepatitis (halothane, minocycline) | Rare | Low-titer Anti-LKM; disappear upon discontinuation of the drug |
Treatment of autoimmune hepatitis type 2
HAV is generally responsive to immunosuppressive therapy, which should be initiated quickly after diagnosis confirmation to prevent progression to cirrhosis. Treatment is managed by a hepatologist or a specialized gastroenterologist, with regular monitoring of the biological and serological response.
- Induction corticosteroid therapy: oral prednisone in decreasing doses; expected biological response in 2 to 4 weeks
- Azathioprine as maintenance treatment: allows for the gradual reduction of corticosteroids and decreases relapses
- Mycophenolate mofetil: alternative to azathioprine in case of intolerance or ineffectiveness
- Biological monitoring: transaminases, IgG, and anti-LKM-1 titer at regular intervals
- Follow-up liver biopsy: recommended before any attempt at therapeutic drug withdrawal
- Liver transplantation: reserved for refractory forms or decompensated cirrhosis
Place in the overall autoimmune liver profile
Anti-LKM antibodies are integrated into a structured serological assessment that includes several other hepatic autoantibodies. Their interpretation must consider the overall serological profile, the clinical presentation, and the hepatic biological results.
| Antibodies | Main association | Relationship with Anti-LKM |
|---|---|---|
| Anti-smooth muscle antibody (ASMA) | Type 1 diabetes | Mutually exclusive with anti-LKM-1 in the vast majority of cases |
| Anti-nuclear antibodies (ANA/FAN) | Type 1 diabetes, SLE, other connective tissue diseases | Generally negative in pure HAI-2; if positive, suggest overlap |
| Anti-LC1 (anti-liver cytosol) | Type 2 diabetes | Often co-positive with anti-LKM-1; can be the only positive marker in early HAI-2 |
| Anti-mitochondrial antibodies (AMA-M2) | Primary biliary cholangitis (PBC) | Absent in HAI-2; their presence points towards PBC or an overlap syndrome |
| Anti-SLA/LP (soluble liver antigen) | Severe type 1 and 2 diabetes | Marker of poor prognosis; may coexist with anti-LKM in severe forms |
| pANCA | Type 1 AIH, primary sclerosing cholangitis | Absent from the HAI-2; useful for differential diagnosis |
Consult at Clinique Omicron
Clinique Omicron offers, at its service points in Quebec, a comprehensive medical evaluation for patients with unexplained elevations in liver enzymes, jaundice of undetermined origin, or suspected autoimmune liver disease. Our physicians are able to order and interpret the appropriate liver serology panel, including anti-LKM antibodies, anti-LC1, ASMA, and AMA, and then refer to a gastroenterologist or hepatologist when necessary. Book an appointment at one of our service points on the South Shore or at one of our branches in Quebec. Teleconsultation is also available for a first evaluation or a review of lab results.
The content of this page is provided for informational purposes only and is not intended to replace the advice of a qualified healthcare professional. Consult a physician for any symptoms, questions or decisions you may have regarding your health.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.